212 related articles for article (PubMed ID: 15847387)
1. Value of immunohistochemistry in confirming undifferentiated ovarian carcinomas.
Georgescu CV; Florescu M; Simionescu C
Rom J Morphol Embryol; 1999-2004; 45():133-42. PubMed ID: 15847387
[TBL] [Abstract][Full Text] [Related]
2. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
3. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
4. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
5. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ
J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
[TBL] [Abstract][Full Text] [Related]
6. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
7. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
Ordóñez NG
Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
[TBL] [Abstract][Full Text] [Related]
8. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
9. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma.
Cameron RI; Ashe P; O'Rourke DM; Foster H; McCluggage WG
Int J Gynecol Pathol; 2003 Jul; 22(3):272-6. PubMed ID: 12819395
[TBL] [Abstract][Full Text] [Related]
10. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
Takeshima Y; Amatya VJ; Kushitani K; Inai K
Am J Clin Pathol; 2008 Nov; 130(5):771-9. PubMed ID: 18854270
[TBL] [Abstract][Full Text] [Related]
11. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas.
van Niekerk CC; Boerman OC; Ramaekers FC; Poels LG
Am J Pathol; 1991 Feb; 138(2):455-63. PubMed ID: 1992770
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
13. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
Ordóñez NG
Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
[TBL] [Abstract][Full Text] [Related]
14. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.
Lagendijk JH; Mullink H; Van Diest PJ; Meijer GA; Meijer CJ
Hum Pathol; 1998 May; 29(5):491-7. PubMed ID: 9596273
[TBL] [Abstract][Full Text] [Related]
15. So-called peritoneal implants of ovarian carcinomas. Problems in differential diagnosis.
Dienemann D; Pickartz H
Pathol Res Pract; 1987 Apr; 182(2):195-201. PubMed ID: 3601795
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
Baker PM; Oliva E
Int J Gynecol Pathol; 2005 Jan; 24(1):39-55. PubMed ID: 15626916
[TBL] [Abstract][Full Text] [Related]
17. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: A study of 160 cases.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Feb; 31(2):255-66. PubMed ID: 17255771
[TBL] [Abstract][Full Text] [Related]
19. Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries.
Heinzelmann-Schwarz VA; Scolyer RA; Scurry JP; Smith AN; Gardiner-Garden M; Biankin AV; Baron-Hay S; Scott C; Ward RL; Fink D; Hacker NF; Sutherland RL; O'Brien PM
J Clin Pathol; 2007 Jun; 60(6):622-6. PubMed ID: 16822880
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological analysis and differential diagnosis of primary peritoneal adenocarcinoma].
Gong HL; Wang CB; Zhang GJ; Li CF; Yang XY; Hou HL; Zhang XB
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):463-5. PubMed ID: 19567094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
